Streetbeat News

Earnings

RLYB

Rallybio (NASDAQ:RLYB) reported Q2 losses of $(0.46) per share, beating the analyst consensus estimate of $(0.48) by 4.17 percent. This represents a 19.3 percent increase over losses of $(0.57) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:24 pm

INGR

Ingredion Inc (NYSE:INGR) reported Q2 FY23 sales growth of 1.2% year-on-year to $2.07 billion, missing the analyst consensus of $2.20 billion. Adjusted EPS of $2.32 also missed the analyst consensus of $2.33. The company declared a quarterly dividend of $0.78 per share, an increase of 9.9% over the previous quarter's dividend. However, INGR shares traded lower by 4.20% at $105.00 premarket on the last check Tuesday.

Portfolio Pulse from Shivani Kumaresan

August 08, 2023 | 12:20 pm

COGT

Cogent Biosciences reported Q2 losses of $(0.59) per share, missing the analyst consensus estimate of $(0.55) by 7.27 percent. However, this is a 16.9 percent improvement over losses of $(0.71) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:20 pm

KMI

MCK

PINS

UNM

Insiders at Kinder Morgan (KMI), Unum Group (UNM), Pinterest (PINS), and McKesson (MCK) have recently sold significant amounts of shares. Kinder Morgan's VP sold shares following weaker-than-expected Q2 sales. Unum Group's EVP sold shares after the company reported better-than-expected Q2 results. Pinterest's former CFO sold shares after the company reported a 6% YoY increase in Q2 revenue. McKesson's CEO sold shares following upbeat quarterly results.

Portfolio Pulse from Lisa Levin

August 08, 2023 | 12:20 pm

AYX

BPTS

BYND

CHGG

HIMS

INFI

PTRA

Several stocks are experiencing significant pre-market movements. Infinity Pharmaceuticals (INFI) surged 83.5% after announcing plans to reduce headcount by 78%. Biophytis (BPTS) rose 59.4% following positive opinion from Belgian authorities for its SARA-31 Phase 3 study. Chegg (CHGG) gained 23.4% after reporting better-than-expected quarterly sales. Hims & Hers Health (HIMS) climbed 17.2% after posting upbeat Q2 results and raising full-year revenue forecast. Proterra (PTRA) fell 63% after filing for Chapter 11 bankruptcy. Alteryx (AYX) fell 25% after issuing weak Q3 revenue guidance. Beyond Meat (BYND) fell 16% after reporting downbeat Q2 results and issuing weak revenue forecast for FY23.

Portfolio Pulse from Lisa Levin

August 08, 2023 | 12:20 pm

MRSN

Mersana Therapeutics reported Q2 earnings per share (EPS) of $(0.47), beating the analyst consensus estimate of $(0.50) by 6%. This is a 14.55% increase over losses from the same period last year. The company also reported quarterly sales of $10.65M, beating the analyst consensus estimate of $8.45M by 26.08%. This is a 148.69% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:19 pm

NVEE

NV5 has acquired Red Technologies, a move that strengthens its data center and mission critical services in the Asia Pacific region. The acquisition was made with a combination of cash and stock and is expected to be immediately accretive to NV5's earnings.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:18 pm

CRBP

Corbus Pharmaceuticals reported Q2 losses of $(2.05) per share, beating the analyst consensus estimate of $(3.10) by 33.87 percent. This represents a 2.38 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:17 pm

NUWE

Nuwellis reported Q2 earnings per share (EPS) of $(3.65), beating the analyst consensus estimate of $(4.02) by 9.2%. However, the company's quarterly sales of $2.07 million missed the estimate of $2.19 million by 5.48%. Compared to the same period last year, the EPS increased by 91.1% while sales decreased by 6.46%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:16 pm

TPG

TPG reported Q2 earnings of $0.26 per share, missing the analyst consensus estimate of $0.34 by 23.53%. This is a 43.48% decrease from the same period last year. However, the company reported quarterly sales of $327.10 million, beating the analyst consensus estimate of $295.21 million by 10.80%. This is a 12.81% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:10 pm